SGLT2i NEUROPROTECTIVE PROPERTIES IN DEPRESSION, AUTISM SPECTRUM DISORDER AND EPILEPSY
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6321Keywords:
SGLT2i, Neuroprotection, Depression, Autism Spectrum Disorder, EpilepsyAbstract
SGLT2i (sodium-glucose cotransporter 2 inhibitors) are a class of medications widely used in the treatment of diabetic, cardiology and nephrology conditions. Beyond cardioprotection and nephroprotection there are reports that SGLT2i demonstrate additional neuroprotective properties.
This article focuses on the clinical features of central nervous system disorders including epilepsy, autism spectrum disorder and major depression. We also describe current approach to their therapy and discuss possible treatment options placing the main emphasis on the SGLT2 inhibitors and their potential neuroprotective properties.
Methods and materials: A qualitative synthesis of the data focusing on SGLT2i neuroprotective properties in central nervous system was performed. This literature review of SGLT2i effect on major depression, autism spectrum disorder and epilepsy included recent publications, primarily from the past 10 years, and was conducted from January 2026 to July 2026 using the PubMed database.
A systematic search was performed using specific keywords and medical subject headings (MeSH terms) related to SGLT2i, depression, autism spectrum disorder and epilepsy. The primary search terms included: “diabetes mellitus”, “SGLT2i”, “depression”, “autism spectrum disorder”, “epilepsy”, “flozins”, and “neuroprotection”. The criteria for inclusion of articles were as follows: published before July 2026, written in English, peer-reviewed original research articles. Exclusion criteria included publications not available in full text, articles in languages other than English. Editorials, commentaries, and conference abstracts without full data were also excluded. Titles and abstracts of the retrieved articles were screened to determine eligibility based on the inclusion and exclusion criteria.
Aim of the study: In this literature review, we aim to provide an integrated overview of neuroprotective properties of SGLT2i and assess their current perspectives in treatment of central nervous system disorders including depression, autism spectrum disorder and epilepsy.
References
Gu, N., Park, S. I., Chung, H., Jin, X., Lee, S., & Kim, T. E. (2020). Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor. Transl. Clin. Pharmacol, 28(1), 17. https://doi.org/10.12793/TCP.2020.28.E4
Mosley Ii, J. F., Smith, L., Everton, E., & Fellner, C. (2015). Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: A drug class overview. Pharmacy and Therapeutics, 40(7).
Simes, B. C., & Mac Gregor, G. G. (2019). Sodium-glucose cotransporter-2 (SGLT2) inhibitors: A clinician’s guide. Diabetes Metab. Syndr. Obes, 12, 2125. https://doi.org/10.2147/DMSO.S212003
Wiciński, M., Wódkiewicz, E., Górski, K., Walczak, M., & Malinowski, B. (2020). Perspective of sglt2 inhibition in treatment of conditions connected to neuronal loss: Focus on Alzheimer’s disease and ischemia-related brain injury. MDPI AG. https://doi.org/10.3390/ph13110379
Liu, J., et al. (2017). Effects of SGLT2 inhibitors on utis and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis. Sci. Rep, 7(1). https://doi.org/10.1038/s41598-017-02733-w
Skrabic, R., et al. (2022). SGLT2 inhibitors in chronic kidney disease: From mechanisms to clinical practice. MDPI. https://doi.org/10.3390/biomedicines10102458
Abdelgadir, E., Rashid, F., Bashier, A., & Ali, R. (2018). SGLT-2 inhibitors and cardiovascular protection: Lessons and gaps in understanding the current outcome trials and possible benefits of combining SGLT-2 inhibitors with GLP-1 agonists. J. Clin. Med. Res, 10(8), 615–625. https://doi.org/10.14740/jocmr3467w
Goldenberg, R. M., et al. (2016). SGLT2 inhibitor–associated diabetic ketoacidosis: Clinical review and recommendations for prevention and diagnosis. Clin. Ther, 38(12), 2654–2664.e1. https://doi.org/10.1016/j.clinthera.2016.11.002
Ogawa, W., & Sakaguchi, K. (2016). Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors. J. Diabetes Investig, 7(2), 135–138. https://doi.org/10.1111/JDI.12401
Saisho, Y. (2020). SGLT2 inhibitors: The star in the treatment of type 2 diabetes? Diseases. https://doi.org/10.3390/diseases8020014
Vasilakou, D., et al. (2013). Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis. Ann. Intern. Med, 159(4), 262–274. https://doi.org/10.7326/0003-4819-159-4-201308200-00007
Salvatore, T., et al. (2022). An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int. J. Mol. Sci, 23(7). https://doi.org/10.3390/IJMS23073651
Thijs, R. D., Surges, R., O’Brien, T. J., & Sander, J. W. (2019). Epilepsy in adults. Lancet, 393(10172), 689–701. https://doi.org/10.1016/S0140-6736(18)32596-0
Fiest, K. M., et al. (2017). Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology, 88(3), 296–303. https://doi.org/10.1212/WNL.0000000000003509
Sultana, B., et al. (2021). Incidence and prevalence of drug-resistant epilepsy: A systematic review and meta-analysis. Neurology, 96(17), 805–817. https://doi.org/10.1212/WNL.0000000000011839
Mastrangelo, M., Tromba, V., Silvestri, F., & Costantino, F. (2019). Epilepsy in children with type 1 diabetes mellitus: Pathophysiological basis and clinical hallmarks. Eur. J. Paediatr. Neurol, 23(2), 240–247. https://doi.org/10.1016/J.EJPN.2018.12.006
Lu, C. L., Chang, Y. H., Sun, Y., & Li, C. Y. (2018). A population-based study of epilepsy incidence in association with type 2 diabetes and severe hypoglycaemia. Diabetes Res. Clin. Pract, 140, 97–106. https://doi.org/10.1016/J.DIABRES.2018.03.020
Shlobin, N. A., & Sander, J. W. (2020). Drivers for the comorbidity of type 2 diabetes mellitus and epilepsy: A scoping review. Epilepsy Behav, 106. https://doi.org/10.1016/J.YEBEH.2020.107043
Erdogan, M. A., et al. (2018). Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy. BMC Neurol, 18(1). https://doi.org/10.1186/S12883-018-1086-4
Ochoa, J. G., Dougherty, M., Papanastassiou, A., Gidal, B., Mohamed, I., & Vossler, D. G. (2021). Treatment of super-refractory status epilepticus: A review. Epilepsy Curr, 21(6), 405–415. https://doi.org/10.1177/1535759721999670
Sampaio, L. P. de B. (2016). Ketogenic diet for epilepsy treatment. Arq. Neuropsiquiatr, 74(10), 842–848. https://doi.org/10.1590/0004-282X20160116
Juge, N., et al. (2010). Metabolic control of vesicular glutamate transport and release. Neuron, 68(1), 99–112. https://doi.org/10.1016/J.NEURON.2010.09.002
Youm, Y. H., et al. (2015). The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med, 21(3), 263–269. https://doi.org/10.1038/NM.3804
Maalouf, M., Sullivan, P. G., Davis, L., Kim, D. Y., & Rho, J. M. (2007). Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience, 145(1), 256–264. https://doi.org/10.1016/J.NEUROSCIENCE.2006.11.065
Sampaio, L. P. de B. (2016). Ketogenic diet for epilepsy treatment. Arq. Neuropsiquiatr, 74(10), 842–848. https://doi.org/10.1590/0004-282X20160116
Cervenka, M. C., et al. (2017). Phase I/II multicenter ketogenic diet study for adult superrefractory status epilepticus. Neurology, 88(10), 938–943. https://doi.org/10.1212/WNL.0000000000003690
Thakur, K. T., et al. (2014). Ketogenic diet for adults in super-refractory status epilepticus. Neurology, 82(8), 665–670. https://doi.org/10.1212/WNL.0000000000000151
Blunck, J. R., Newman, J. W., Fields, R. K., & Croom, J. E. (2018). Therapeutic augmentation of ketogenic diet with a sodium-glucose cotransporter 2 inhibitor in a super-refractory status epilepticus patient. Epilepsy Behav. Case Rep, 10, 61–64. https://doi.org/10.1016/J.EBCR.2018.05.002
Chaste, P., & Leboyer, M. (2012). Autism risk factors: Genes, environment, and gene-environment interactions. Dialogues Clin. Neurosci, 14(3), 281. https://doi.org/10.31887/DCNS.2012.14.3/PCHASTE
Nakhal, M. M., Aburuz, S., Sadek, B., & Akour, A. (2022). Repurposing SGLT2 inhibitors for neurological disorders: A focus on the autism spectrum disorder. Molecules, 27(21), 7174. https://doi.org/10.3390/molecules27217174
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021). Neuroprotective effect of SGLT2 inhibitors. MDPI. https://doi.org/10.3390/molecules26237213
Singh, A. G. K., Unnikrishnan, A., Zargar, A. H., Kumar, A., Das, A. K., Saboo, B., Sinha, B., Gangopadhyay, K. K., Talwalkar, P. G., Ghosal, S., Kalra, S., Joshi, S., Sharma, S. K., Sriram, U., Mohan, V., et al. (2019). Evidence-based consensus on positioning of SGLT2i in type 2 diabetes mellitus in indians. Diabetes Therapy, 10. https://doi.org/10.6084/m9.figshare.7546997
Dong, M., Wen, S., & Zhou, L. (2022). The relationship between the blood-brain-barrier and the central effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors. Diabetes Metab. Syndr. Obes, 15, 2583–2597. https://doi.org/10.2147/DMSO.S375559
Hou, Y.-C., Zheng, C.-M., Yen, T.-H., & Lu, K.-C. (2020). Molecular sciences molecular mechanisms of SGLT2 inhibitor on cardiorenal protection. Int. J. Mol. Sci. https://doi.org/10.3390/ijms21217833
Heerspink, H. J. L., et al. (2019). Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia, 62(7), 1154–1166. https://doi.org/10.1007/S00125-019-4859-4
Tian, J., et al. (2021). Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via ampkα/tgf-β/smad signalling in type 2 diabetic rats. J. Cell. Mol. Med, 25(16), 7642–7659. https://doi.org/10.1111/JCMM.16601
Jayarathne, H. S. M., et al. (2022). Neuroprotective effects of canagliflozin: Lessons from aged genetically diverse UM-HET3 mice. Aging Cell, 21. https://doi.org/10.1111/acel.13653
Malgaroli, M., Calderon, A., & Bonanno, G. A. (2021). Networks of major depressive disorder: A systematic review. Clin. Psychol. Rev, 85(January), 102000. https://doi.org/10.1016/j.cpr.2021.102000
Mchugh, R. K., & Weiss, R. D. (2019). Alcohol use disorder and depressive disorders. Alcohol Res, 40(1), e1–e8. https://doi.org/10.35946/arcr.v40.1.01
Moulton, C. D., Pickup, J. C., & Ismail, K. (2015). The link between depression and diabetes: The search for shared mechanisms. Lancet Diabetes Endocrinol, 3(6), 461–471. https://doi.org/10.1016/S2213-8587(15)00134-5
Gonzalez, J. S., Fisher, L., & Polonsky, W. H. (2011). Depression in diabetes: Have we been missing something important? Diabetes Care, 34(1), 236–239. https://doi.org/10.2337/dc10-1970
Wium-Andersen, I. K., Osler, M., Jørgensen, M. B., Rungby, J., & Wium-Andersen, M. K. (2022). Diabetes, antidiabetic medications and risk of depression – a population-based cohort and nested case-control study. Psychoneuroendocrinology, 140(August 2021). https://doi.org/10.1016/j.psyneuen.2022.105715
Muhammad, R. N., Ahmed, L. A., Abdul Salam, R. M., Ahmed, K. A., & Attia, A. S. (2021). Crosstalk among NLRP3 inflammasome, ETBR signaling, and miRNAs in stress-induced depression-like behavior: A modulatory role for SGLT2 inhibitors. Neurotherapeutics, 18(4), 2664–2681. https://doi.org/10.1007/s13311-021-01140-4
Chung, S., Yao, H., Caito, S., Hwang, J. W., Arunachalam, G., & Rahman, I. (2010). Regulation of SIRT1 in cellular functions: Role of polyphenols. Arch. Biochem. Biophys, 501(1), 79–90. https://doi.org/10.1016/j.abb.2010.05.003
Rahman, S., & Islam, R. (2011). Mammalian Sirt1: Insights on its biological functions. Cell Communication and Signaling, 9, 1–8. https://doi.org/10.1186/1478-811X-9-11
Ong, A. L. C., & Ramasamy, T. S. (2018). Role of sirtuin1-p53 regulatory axis in aging, cancer and cellular reprogramming. Ageing Res. Rev, 43(January), 64–80. https://doi.org/10.1016/j.arr.2018.02.004
Martins, I. J., Wilson, A. C., Lim, W. L. F., Laws, S. M., Fuller, S. J., & Martins, R. N. (2012). Sirtuin-1 mediates the obesity induced risk of common degenerative diseases: Alzheimer’s disease, coronary artery disease and type 2 diabetes. Health N. Hav, 04(12), 1448–1456. https://doi.org/10.4236/health.2012.412a209
de Pablos, R. M., Espinosa-Oliva, A. M., Hornedo-Ortega, R., Cano, M., & Arguelles, S. (2019). Hydroxytyrosol protects from aging process via AMPK and autophagy; a review of its effects on cancer, metabolic syndrome, osteoporosis, immune-mediated and neurodegenerative diseases. Pharmacol. Res, 143(March), 58–72. https://doi.org/10.1016/j.phrs.2019.03.005
Osum, M., & Serakinci, N. (2020). Impact of circadian disruption on health; SIRT1 and telomeres. DNA Repair (Amst), 96(June), 102993. https://doi.org/10.1016/j.dnarep.2020.102993
Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nat. Rev. Mol. Cell Biol, 22(2), 119–141. https://doi.org/10.1038/s41580-020-00313-x
Massudi, H., Grant, R., Braidy, N., Guest, J., Farnsworth, B., & Guillemin, G. J. (2012). Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One, 7(7), 1–9. https://doi.org/10.1371/journal.pone.0042357
Sarubbo, F., Esteban, S., Miralles, A., & Moranta, D. (2017). Effects of resveratrol and other polyphenols on Sirt1: Relevance to brain function during aging. Curr. Neuropharmacol, 16(2), 126–136. https://doi.org/10.2174/1570159x15666170703113212
Jiao, F., & Gong, Z. (2020). The beneficial roles of SIRT1 in neuroinflammation-related diseases. Oxid. Med. Cell. Longev, 2020. https://doi.org/10.1155/2020/6782872
Chong, Z. Z., Wang, S., Shang, Y. C., & Maiese, K. (2012). Targeting cardiovascular disease with novel SIRT1 pathways. Future Cardiol, 8(1), 89–100. https://doi.org/10.2217/fca.11.76
Khayatan, D., et al. (2022). Regulatory effects of statins on SIRT1 and other sirtuins in cardiovascular diseases. 12(5), 1–14. https://doi.org/10.3390/life12050760
Matsushima, S., & Sadoshima, J. (2015). The role of sirtuins in cardiac disease. Am. J. Physiol. Heart Circ. Physiol, 309(9), H1375–H1389. https://doi.org/10.1152/ajpheart.00053.2015
Manjula, R., Anuja, K., & Alcain, F. J. (2021). SIRT1 and SIRT2 activity control in neurodegenerative diseases. Front. Pharmacol, 11(January), 1–26. https://doi.org/10.3389/fphar.2020.585821
Mishra, P., et al. (2020). SIRT1 promotes neuronal fortification in neurodegenerative diseases through attenuation of pathological hallmarks and enhancement of cellular lifespan. Curr. Neuropharmacol, 19(7), 1019–1037. https://doi.org/10.2174/1570159x18666200729111744
Donmez, G., & Outeiro, T. F. (2013). SIRT1 and SIRT2: Emerging targets in neurodegeneration. EMBO Mol. Med, 5(3), 344–352. https://doi.org/10.1002/emmm.201302451
Li, X., Feng, Y., Wang, X. X., Truong, D., & Wu, Y. C. (2020). The critical role of SIRT1 in Parkinson’s disease: Mechanism and therapeutic considerations. Aging Dis, 11(6), 1608–1622. https://doi.org/10.14336/AD.2020.0216
Chojdak-Łukasiewicz, J., Bizoń, A., Waliszewska-Prosół, M., Piwowar, A., Budrewicz, S., & Pokryszko-Dragan, A. (2022). Role of sirtuins in physiology and diseases of the central nervous system. Biomedicines, 10(10), 1–19. https://doi.org/10.3390/biomedicines10102434
Song, J., & Kim, J. (2016). Role of sirtuins in linking metabolic syndrome with depression. Front. Cell. Neurosci, 10(MAR2016), 1–9. https://doi.org/10.3389/fncel.2016.00086
Zhang, Y., Anoopkumar-Dukie, S., & Davey, A. K. (2021). Sirt1 and sirt2 modulators: Potential anti-inflammatory treatment for depression? Biomolecules, 11(3), 1–9. https://doi.org/10.3390/biom11030353
Kim, H. D., et al. (2016). SIRT1 mediates depression-like behaviors in the nucleus accumbens. Journal of Neuroscience, 36(32), 8441–8452. https://doi.org/10.1523/JNEUROSCI.0212-16.2016
Wang, J., et al. (2021). Ameliorative effect of SIRT1 in postpartum depression mediated by upregulation of the glucocorticoid receptor. Neurosci. Lett, 761(June), 136112. https://doi.org/10.1016/j.neulet.2021.136112
Lu, G., Li, J., Zhang, H., Zhao, X., Yan, L. J., & Yang, X. (2018). Role and possible mechanisms of sirt1 in depression. Oxid. Med. Cell. Longev, 2018. https://doi.org/10.1155/2018/8596903
Kitada, M., Ogura, Y., Monno, I., & Koya, D. (2019). Sirtuins and type 2 diabetes: Role in inflammation, oxidative stress, and mitochondrial function. Front. Endocrinol. (Lausanne), 10(MAR), 1–12. https://doi.org/10.3389/fendo.2019.00187
Zhou, S., Tang, X., & Chen, H. Z. (2018). Sirtuins and insulin resistance. Front. Endocrinol. (Lausanne), 9(December). https://doi.org/10.3389/fendo.2018.00748
Kitada, M., & Koya, D. (2013). SIRT1 in type 2 diabetes: Mechanisms and therapeutic potential. Diabetes Metab. J, 37(5), 315–325. https://doi.org/10.4093/dmj.2013.37.5.315
Lingappa, N., & Mayrovitz, H. N. (2022). Role of sirtuins in diabetes and age-related processes. Cureus, 14(9). https://doi.org/10.7759/cureus.28774
Li, J., Zhou, L., & Gong, H. (2022). New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure. Front. Cardiovasc. Med, 9. https://doi.org/10.3389/fcvm.2022.903902
Hoong, C. W. S., & Chua, M. W. J. (2021). SGLT2 inhibitors as calorie restriction mimetics: Insights on longevity pathways and age-related diseases. Endocrinology (United States), 162(8), 1–20. https://doi.org/10.1210/endocr/bqab079
Packer, M. (2020). Cardioprotective effects of sirtuin-1 and its downstream effectors: Potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors. Circ. Heart Fail, 13(9), E007197. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007197
Lee, J. Y., et al. (2021). Ipragliflozin, an SGLT2 inhibitor, ameliorates high-fat diet-induced metabolic changes by upregulating energy expenditure through activation of the AMPK/ SIRT1 pathway. Diabetes Metab. J, 45(6), 921–932. https://doi.org/10.4093/dmj.2020.0187
Wang, Y. J., Paneni, F., Stein, S., & Matter, C. M. (2021). Modulating sirtuin biology and nicotinamide adenine diphosphate metabolism in cardiovascular disease—from bench to bedside. Front. Physiol, 12(October). https://doi.org/10.3389/fphys.2021.755060
Tovar-Palacio, C., Noriega, L. G., & Mercado, A. (2022). Potential of polyphenols to restore SIRT1 and NAD+ metabolism in renal disease. Nutrients, 14(3), 1–33. https://doi.org/10.3390/nu14030653
Deschaine, B., Verma, S., & Rayatzadeh, H. (2022). Clinical evidence and proposed mechanisms of sodium–glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A class effect? Card. Fail. Rev, 8(Cv). https://doi.org/10.15420/cfr.2022.11
Gao, Y. M., Feng, S. T., Wen, Y., Tang, T. T., Wang, B., & Liu, B. C. (2022). Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming. EBioMedicine, 83, 104215. https://doi.org/10.1016/j.ebiom.2022.104215
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dominik Zając, Dominika Darasz, Jakub Jucha, Izabela Ochońska, Oliwia Dziewięcka, Wojciech Ziębka, Michał Krzysztof Żołyński, Marta Kaczorek, Krzysztof Machnik, Marek Łobaziewicz
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
